Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IL4I1 | Q96RQ9 | 1/20 | 0.45 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.45 |
| ▸ | HTR1A | P08908 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.41 |
| ▸ | PGR | P06401 | 1/20 | 0.41 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.41 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.41 |
| ▸ | CES1 | P23141 | 1/20 | 0.41 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.40 |
| ▸ | CDK1 | P06493 | 1/20 | 0.40 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.40 |
| ▸ | GSK3B | P49841 | 1/20 | 0.40 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.40 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.40 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.40 |
| ▸ | MMP12 | P39900 | 1/20 | 0.40 |
| ▸ | BRD4 | O60885 | 2/20 | 0.40 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.40 |
| ▸ | AHR | P35869 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31170719 | 1.00 | IL4I1 (0.45) | IL4I1SMYD3HTR1ADRD2NR3C1 | |
| SCHEMBL9048241 | 0.81 | CES1 (0.51) | IL4I1CES1CCNB2CDK1CCNB1 | |
| SCHEMBL3590076 | 0.80 | SMYD3 (0.46) | SMYD3HTR1ADRD2MMP12BRD4 | |
| SCHEMBL254031 | 0.79 | SMYD3 (0.48) | SMYD3HTR1ADRD2MMP12BRD4 | |
| SCHEMBL1851941 | 0.79 | CREBBP (0.58) | SMYD3HTR1ADRD2NR3C1PGR | |
| SCHEMBL4317646 | 0.79 | SMYD3 (0.51) | SMYD3HTR1ADRD2MMP12BRD4 | |
| SCHEMBL22521052 | 0.79 | SMYD3 (0.45) | SMYD3HTR1ADRD2MMP12BRD4 | |
| SCHEMBL2380905 | 0.79 | SMYD3 (0.45) | SMYD3HTR1ADRD2CCNB2CDK1 | |
| SCHEMBL2599615 | 0.79 | SMYD3 (0.45) | SMYD3HTR1ADRD2NR3C1PGR | |
| SCHEMBL31170800 | 0.79 | CES1 (0.41) | IL4I1SMYD3HTR1ADRD2NR3C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3080115-B1 | FUSED IMIDAZOLE AND PYRAZOLE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB BIOPHARMA SPRL (BE) | 2019-05-08 | — | — | EP | disclosed |
| US-9868749-B2 | Fused imidazole and pyrazole derivatives as modulators of TNF activity | UCB BIOPHARMA SPRL (BE) | 2018-01-16 | — | — | US | disclosed |
| EP-3080115-A1 | FUSED IMIDAZOLE AND PYRAZOLE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB Biopharma SPRL (BE) | 2016-10-19 | — | — | EP | disclosed |
| US-20160297837-A1 | Fused Imidazole and Pyrazole Derivatives As Modulators of TNF Activity | EVOTEC (UK) LTD. (GB) | 2016-10-13 | — | — | US | disclosed |
| WO-2015086506-A1 | FUSED IMIDAZOLE AND PYRAZOLE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB BIOPHARMA SPRL (BE) | 2015-06-18 | — | — | WO | disclosed |
| EP-2048136-A1 | PHYTOTOXIC HALOGENATED DERIVATIVES OF BENZOXAZINONES | Universidad de Cadiz (ES) | 2009-04-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160297837-A1 | Fused Imidazole and Pyrazole Derivatives As Modulators of TNF Activity | TNF, TNFRSF1A, TNFRSF9 | IL4I1 208/4885SMYD3 4505/4885HTR1A 1699/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.